Usefulness of Cardiac Troponins as Markers of Early Treatment Response in XXXX .

@entity1 @entity1165 @entity944 @entity713 @entity6949 @entity10020 @entity299 @entity204 @entity479
Evaluation and treatment of @entity299 ( @entity299 ) suffer from lack of sensitive and easily repeatable markers of disease activity. We studied measurements of high-sensitivity cardiac troponin T or troponin I (hs- @entity10020 /I) taken at presentation and during treatment in 62 @entity1 with new-onset @entity299 (48 @entity1 , mean age 49 years). Hs- @entity10020 was measured in 50 @entity1 and was elevated (>13 ng/L) at presentation in 26 of them (52%). Hs- @entity6949 was measured in the remaining 12 @entity1 and was elevated (>0.04 ng/mL) in 7 of them (58%). Left ventricular ejection fraction averaged 43    14% in association with elevated hs- @entity10020 /I (n = 33) versus 53    10% with normal hs- @entity10020 /I (n = 29; p = 0.001). Hs- @entity10020 /I was remeasured after 4 weeks of @entity479 therapy in 38 @entity1 and was normalized in 16 of the 24 (67%) with an elevated pretreatment concentration and remained normal in the rest of the 14 @entity1 (p <0.001). During follow-up (median, 17 months), @entity204 (n = 2), aborted @entity944 (n = 5), sustained @entity1165 (n = 8), or new complete @entity713 (n = 1) was recorded in 11 of 33 @entity1 with elevated hs- @entity10020 /I versus in 5 of 29 with normal hs- @entity10020 /I (log-rank p = 0.068). Two-year event-free Kaplan-Meier cardiac survival estimate (95% confidence interval) was 67% (48% to 81%) with elevated hs- @entity10020 /I versus 93% (76% to 99%) with normal hs- @entity10020 /I. In @entity299 , circulating hs- @entity10020 /I may help clinicians evaluate disease activity and treatment response. Their prognostic value remains tentative pending more follow-up data.
